Corporate | 11 May 2006 11:26

Geratherm Medical AG:Apoplex study reveals clear positive result

Corporate-news transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Corporate News Geratherm/Apoplex study reveals clear positive results Geschwenda/Pirmasens/Athens, May 11, 2006 – Geratherm Medical AG (Frankfurter Börse, ISIN: DE 0005495626, WKN: 549 562). Geratherms subsidiary apoplex medical technologies GmbH presents today the results of an extended study with its Stroke Risk Analyzer IV at the EuroPrevent2006 which is held in Athens (Greece). The EuroPrevent2006 is the first annual congress of the European Association for Cardiovascular Prevention and Rehabilitation organised by the European Society of Cardiology. The study was carried out in collaboration with Prof. Heuer at the St. Johannes Hospital, Dortmund (Germany). The results clearly demonstrate that the algorithm imbedded in the Stroke Risk Analyser IV is able to identify patients with atrial fibrillation (Afib) between fibrillation episodes. The study is based on 1083 hours of electrocardiographical recordings. Functional and structural changes in the atrium of patients suffering from Afib change the heart rhythm. Those deviations from the normal heart rate dynamics may still be present outside of fibrillation episodes. Especially in the early phase of the development of Afib deviations might be small that only mathematical algorithms are able to filter them out. That the Stroke Risk Analyzer IV System is capable of achieving that, was proven by the study. The algorithm was able to identify patients with intermittent Afib with a sensitivity of 79%. The sensitivity for the identification of these patients according to the presence of fibrillation episodes was 22% only. In this study, the ratio of detected hours at risk with the algorithm and detected hours with fibrillation episodes demonstrates a fourfold increased detection rate for the algorithm. The results of the study show that the Stroke Risk Analyser IV is highly suitable to find patients at risk for Afib (Screening). Geratherm Medical AG develops, manufactures, and sales systems that record and transfer vital data. Since 2004 all activities concerning products for stroke prophylaxis have been concentrated in the subsidiary apoplex medical technologies GmbH, Pirmasens (Germany). Geratherm Medical AG, Fahrenheitstraße 1, 98716 Geschwenda Contact: Martina Schramm, Tel.036205/98 111, Fax: 036205/98 115, E-Mail: info@geratherm.com, homepage: www.apoplexmedical.com (c)DGAP 11.05.2006 ————————————————————————— Language: English Issuer: Geratherm Medical AG Fahrenheitstraße 1 98716 Geschwenda Deutschland Phone: +49 (0)36205 98-0 Fax: +49 (0)36205 98-1 15 email: info@geratherm.com WWW: www.geratherm.com ISIN: DE0005495626 WKN: 549562 indices: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service —————————————————————————